From the Department of Psychiatry, Cumming School of Medicine, University of Calgary, Calgary, Alta., Canada (MacQueen, Hassel, Addington, Sharma); the Rotman Research Institute, Baycrest, and Department of Medical Biophysics, University of Toronto, Toronto, Ont., Canada (Arnott, Zamyadi, Strother); the Department of Psychology, Queen’s University, Kingston, Ont., Canada (Bowie, Harkness, Milev); the Department of Radiology, University of Calgary, Calgary, Alta., Canada (Bray, Lebel); the Alberta Children’s Hospital Research Institute, Calgary, Alta., Canada (Bray, Lebel); the Child and Adolescent Imaging Research (CAIR) Program, Calgary, Alta., Canada (Bray, Lebel); the Department of Psychology, Neuroscience and Behaviour, McMaster University, and St. Joseph’s Healthcare Hamilton, Hamilton, Ont., Canada (Hall); the Krembil Research Institute and Centre for Mental Health, University Health Network, Toronto, Ont., Canada (Downar); the Institute of Medical Science, Faculty of Medicine, University of Toronto, Toronto, Ont., Canada (Downar); the Department of Psychiatry, Faculty of Medicine, University of Toronto, Toronto, Ont., Canada (Downar, Müller, Rizvi, Rotzinger, Kennedy); the Department of Psychiatry, Krembil Research Centre, University Health Network, University of Toronto, Toronto, Ont., Canada (Foster, Rotzinger, Kennedy); the Department of Psychiatry and Behavioural Neurosciences, McMaster University, and St. Joseph’s Healthcare Hamilton, Hamilton, Ont., Canada (Foster, Frey); the Centre for Youth Bipolar Disorder, Sunnybrook Health Sciences Centre, Toronto, Ont., Canada (Goldstein); the Departments of Psychiatry and Pharmacology, Faculty of Medicine, University of Toronto, Toronto, Ont., Canada (Goldstein); the Department of Computer Science, University of Alberta, Edmonton, Alta., Canada (Harris); the University of British Columbia and Vancouver Coastal Health Authority, Vancouver, B.C., Canada (Lam, Vila-Rodriguez); the Department of Psychiatry, Queen’s University and Providence Care Hospital, Kingston, Ont., Canada (Milev, Soares); the Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ont., Canada (Müller); the Department of Psychiatry, University of Michigan, Ann Arbor, MI, USA (Parikh); the Arthur Sommer Rotenberg Suicide and Depression Studies Program, Li Ka Shing Knowledge Institute and St. Michael’s Hospital, Toronto, Ont., Canada (Rizvi); the Institute of Medical Science, Faculty of Medicine, University of Toronto, Toronto, Ont., Canada (Rizvi); the Department of Psychiatry, St. Michael’s Hospital, University of Toronto, Toronto, Ont., Canada (Rotzinger, Soares, Yu); McGill University, Montréal, Que., Canada (Turecki); the Douglas Mental Health University Institute, Frank B. Common, Montréal, Que., Canada (Turecki); and the Keenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute, St. Michael’s Hospital, Toronto, Ont., Canada (Kennedy).
J Psychiatry Neurosci. 2019 Jul 1;44(4):223-236. doi: 10.1503/jpn.180036.
Studies of clinical populations that combine MRI data generated at multiple sites are increasingly common. The Canadian Biomarker Integration Network in Depression (CAN-BIND; www.canbind.ca) is a national depression research program that includes multimodal neuroimaging collected at several sites across Canada. The purpose of the current paper is to provide detailed information on the imaging protocols used in a number of CAN-BIND studies. The CAN-BIND program implemented a series of platform-specific MRI protocols, including a suite of prescribed structural and functional MRI sequences supported by real-time monitoring for adherence and quality control. The imaging data are retained in an established informatics and databasing platform. Approximately 1300 participants are being recruited, including almost 1000 with depression. These include participants treated with antidepressant medications, transcranial magnetic stimulation, cognitive behavioural therapy and cognitive remediation therapy. Our ability to analyze the large number of imaging variables available may be limited by the sample size of the substudies. The CAN-BIND program includes a multimodal imaging database supported by extensive clinical, demographic, neuropsychological and biological data from people with major depression. It is a resource for Canadian investigators who are interested in understanding whether aspects of neuroimaging — alone or in combination with other variables — can predict the outcomes of various treatment modalities.
越来越多的研究将来自多个地点的 MRI 数据进行组合分析。加拿大抑郁生物标志物整合网络(CAN-BIND;www.canbind.ca)是一个全国性的抑郁研究项目,包含了在加拿大多个地点采集的多模态神经影像学数据。本研究旨在提供 CAN-BIND 多项研究中所使用的影像学协议的详细信息。CAN-BIND 项目实施了一系列特定于平台的 MRI 协议,包括一系列预设的结构和功能 MRI 序列,并通过实时监测来保证依从性和质量控制。这些影像学数据被保留在一个既定的信息学和数据库平台中。该项目正在招募约 1300 名参与者,其中近 1000 名为抑郁症患者。这些患者包括接受抗抑郁药物治疗、经颅磁刺激、认知行为疗法和认知矫正治疗的患者。我们分析大量影像学变量的能力可能会受到子研究样本量的限制。CAN-BIND 项目包含一个多模态成像数据库,该数据库得到了来自患有重度抑郁症的人群的广泛的临床、人口统计学、神经心理学和生物学数据的支持。它为加拿大研究人员提供了一个资源,他们有兴趣了解神经影像学的各个方面(单独或与其他变量结合)是否可以预测各种治疗方式的结果。